Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Sean Patrick Cleary

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5274-9983; OpenAlex author ID A5023511246. Sources: OpenAlex.

Their work

Papers
44 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
161
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 6 papers · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: 4 papers · 2023: 3 papers · 2024: 4 papers · 2025: 3 papers · 2026: 3 papers

Papers 44

  1. Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid. Co-author DOI 10.1002/jso.70292↗
  2. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. Co-author DOI 10.1093/oncolo/oyag416↗
  3. Irreversible electroporation associated with improved overall survival vs standard of care for stage 3 pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353144↗
  4. Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jso.27871↗
  5. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  6. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Co-author DOI 10.1530/erc-24-0142↗
  7. Early vs conventional onset pancreatic ductal adenocarcinoma: analysis of surgical and oncologic outcomes in patients undergoing curative intent resection. Co-author DOI 10.1016/j.hpb.2023.09.010↗
  8. Quality of Life and Gastrointestinal Symptoms in Long-term Survivors of Pancreatic Cancer Following Pancreatoduodenectomy. Co-author DOI 10.1097/sla.0000000000006053↗
  9. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14875-5↗
  10. Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Regis… Co-author DOI 10.3390/cancers16233894↗
  11. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. Co-author DOI 10.1097/xcs.0000000000000704↗
  12. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  13. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenoc… Co-author DOI 10.1245/s10434-023-14138-3↗
  14. Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance. Co-author DOI 10.1016/j.gastha.2022.07.004↗
  15. Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hpb.2022.06.005↗
  16. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  17. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  18. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4144↗
  19. A Risk Score Model for Locoregional Recurrence Following Upfront Surgery for Pancreatic Adenocarcinoma: Implications for Adjuvant Therapy. Co-author DOI 10.1016/j.clon.2021.03.007↗
  20. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinica… Co-author DOI 10.1016/j.jamcollsurg.2021.05.009↗
  21. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003284↗
  22. En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent. Co-author DOI 10.1016/j.jamcollsurg.2020.05.005↗
  23. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  24. Trajectories of physical activity, from young adulthood to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canad… Co-author DOI 10.1186/s12885-020-6627-8↗
  25. Trajectories of body mass index, from adolescence to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canada. Co-author DOI 10.1007/s10552-019-01197-9↗
  26. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  27. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  28. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  29. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗
  30. The Association of Recently Diagnosed Diabetes and Long-term Diabetes With Survival in Pancreatic Cancer Patients: A Pooled Analysis. Co-author DOI 10.1097/mpa.0000000000000989↗
  31. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2016.3916↗
  32. BRM polymorphisms, pancreatic cancer risk and survival. Last author DOI 10.1002/ijc.30369↗
  33. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.030↗
  34. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Co-author DOI 10.1038/nature19823↗
  35. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  36. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  37. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Co-author DOI 10.1038/nm.3973↗
  38. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/annonc/mdv236↗
  39. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods. First author DOI 10.1245/s10434-014-4196-2↗
  40. Association between alcohol consumption and pancreatic cancer risk: a case-control study. Co-author DOI 10.1371/journal.pone.0124489↗
  41. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/annonc/mdu276↗
  42. Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk. Last author DOI 10.1002/mc.22037↗
  43. Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk. Last author DOI 10.1093/carcin/bgs028↗
  44. Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk Last author DOI 10.1093/carcin/bgs169↗

Closest collaborators

The 25 strongest of 161 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Joseph Truty · 18 shared papers, 2020–2026 · strength 2.85
  2. Michael L. Kendrick · 16 shared papers, 2020–2025 · strength 2.42
  3. Cornelius A. Thiels · 11 shared papers, 2021–2026 · strength 2.04
  4. Susanne Gray Warner · 10 shared papers, 2022–2026 · strength 1.92
  5. Travis Edward Grotz · 11 shared papers, 2020–2026 · strength 1.72
  6. Jennifer A. Yonkus · 8 shared papers, 2021–2025 · strength 1.23
  7. Robert R. McWilliams · 6 shared papers, 2021–2025 · strength 0.94
  8. Steve Gallinger · 16 shared papers, 2012–2021 · strength 0.91
  9. Amro M. Abdelrahman · 6 shared papers, 2021–2025 · strength 0.88
  10. Roberto Alva‐Ruiz · 6 shared papers, 2021–2025 · strength 0.86
  11. Andrea Zironda · 4 shared papers, 2024–2025 · strength 0.84
  12. Patricio Marcelo Polanco · 3 shared papers, 2024–2026 · strength 0.74
  13. Michael D. Kluger · 3 shared papers, 2024–2026 · strength 0.74
  14. Carlos H.F. Chan · 3 shared papers, 2024–2026 · strength 0.74
  15. Rebekah Ruth White · 3 shared papers, 2024–2026 · strength 0.74
  16. Robert C.G. Martin · 3 shared papers, 2024–2026 · strength 0.74
  17. Chi Zhang · 3 shared papers, 2024–2025 · strength 0.65
  18. Amit Mahipal · 4 shared papers, 2021–2025 · strength 0.63
  19. Ayelet Borgida · 10 shared papers, 2012–2020 · strength 0.58
  20. Thorvardur Ragnar Halfdanarson · 4 shared papers, 2021–2025 · strength 0.57
  21. Shounak Majumder · 3 shared papers, 2022–2026 · strength 0.56
  22. Govindarajan Narayanan · 2 shared papers, 2026 · strength 0.54
  23. Chet W. Hammill · 2 shared papers, 2026 · strength 0.54
  24. Michelle Cotterchio · 9 shared papers, 2012–2020 · strength 0.52
  25. Rondell Patrell Graham · 4 shared papers, 2021–2022 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.